loading
Precedente Chiudi:
$0.6231
Aprire:
$0.6232
Volume 24 ore:
464.59K
Relative Volume:
0.74
Capitalizzazione di mercato:
$81.96M
Reddito:
-
Utile/perdita netta:
$-26.91M
Rapporto P/E:
-2.8936
EPS:
-0.22
Flusso di cassa netto:
$-19.57M
1 W Prestazione:
+0.33%
1M Prestazione:
-15.55%
6M Prestazione:
-56.10%
1 anno Prestazione:
-53.53%
Intervallo 1D:
Value
$0.6104
$0.655
Intervallo di 1 settimana:
Value
$0.5914
$0.655
Portata 52W:
Value
$0.5526
$1.81

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name
Nome
Atossa Therapeutics Inc
Name
Telefono
206.588.0256
Name
Indirizzo
10202 5TH AVENUE NE, SEATTLE, WA
Name
Dipendente
13
Name
Cinguettio
@atossainc
Name
Prossima data di guadagno
2025-03-25
Name
Ultimi documenti SEC
Name
ATOS's Discussions on Twitter

Confronta ATOS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ATOS
Atossa Therapeutics Inc
0.6366 81.96M 0 -26.91M -19.57M -0.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2018-01-26 Iniziato Maxim Group Buy

Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie

pulisher
Apr 11, 2025

Atossa Therapeutics (ATOS) Partners with Nona Biosciences to Adv - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Nona Biosciences and Atossa Therapeutics Partner to Discover Nex - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - The Manila Times

Apr 10, 2025
pulisher
Apr 10, 2025

Revolutionary Breast Cancer Treatment Alliance: Next-Gen Antibody Platform Powers New Research Initiative - Stock Titan

Apr 10, 2025
pulisher
Apr 08, 2025

Atossa Therapeutics (NASDAQ:ATOS) & Pharming Group (OTCMKTS:PHGUF) Critical Comparison - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Atossa Therapeutics says Intas Pharmaceuticals Filed Petition For Post Grant Review Against Co- SEC Filing - marketscreener.com

Apr 07, 2025
pulisher
Apr 03, 2025

Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - MSN

Apr 03, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Lowers Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 29, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock By Investing.com - Investing.com Canada

Mar 29, 2025
pulisher
Mar 29, 2025

Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Yahoo

Mar 26, 2025
pulisher
Mar 26, 2025

Atossa Therapeutics Inc (ATOS) Q4 2024 Earnings Call Highlights: - GuruFocus

Mar 26, 2025
pulisher
Mar 26, 2025

Atossa Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Atossa Therapeutics’ Strategic Focus on Z-endoxifen for Breast Cancer Drives Buy Rating - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: Atossa Genetics Q4 2024 beats EPS forecast - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Atossa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

Atossa Therapeutics Inc Reports Q4 EPS of -$0.06, Aligning with Estimates; Revenue Remains at $0 Million - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings Scheduled For March 25, 2025 - Benzinga

Mar 25, 2025
pulisher
Mar 23, 2025

Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Tuesday - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Atossa Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 20, 2025

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Atossa Therapeutics to Host Conference Call for Q4 and Full-Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Atossa Therapeutics Earnings: Key Q4 and 2024 Results Coming March 25How to Listen Live - StockTitan

Mar 20, 2025
pulisher
Mar 15, 2025

Atossa Therapeutics (NASDAQ:ATOS) Given “Buy” Rating at HC Wainwright - The AM Reporter

Mar 15, 2025
pulisher
Mar 14, 2025

HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News

Mar 11, 2025
pulisher
Mar 11, 2025

Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

Atossa targets metastatic breast cancer with (Z)-endoxifen - Investing.com

Mar 11, 2025
pulisher
Mar 04, 2025

Atossa Genetics stock hits 52-week low at $0.72 - Investing.com

Mar 04, 2025
pulisher
Feb 25, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com India

Feb 25, 2025
pulisher
Feb 24, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price - Investing.com

Feb 24, 2025
pulisher
Feb 22, 2025

Atossa Therapeutics reports progress in breast cancer treatments - MSN

Feb 22, 2025
pulisher
Feb 20, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News

Feb 19, 2025

Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):